Industry Relations and Technology Transfer

For Industry/Investors

For Industry/Investors

Technologies available from Fred Hutch

Highlight 1
Muscular Dystrophy (FSHD) Targets
The identification of genes and proteins that damage muscle cells and the mechanisms that cause facioscapulohumeral muscular dystrophy (FSHD), the third most common form of inherited muscular dystrophy, provide opportunities for development of biomarker-based tests to determine risk and diagnose FSHD.
Learn more »
Highlight 2
New Class of Drug Leads
Fred Hutch scientists are developing a new class of drug scaffolds capable of targeting protein-protein interactions. These proprietary drug leads may act as targeting agents for specific imaging and therapeutic applications.
Learn more »
Highlight 3
Accurate, Sensitive and Targeted Sequencing Technologies
Several new sequencing technologies combine to provide a foundational platform for the detection and sequencing of rare mutations and rare cells with extraordinary sensitivity and accuracy.
Learn more »
Highlight 4
Improved Screening Platform and Cancer Therapeutic Targets
An efficient high-throughput screening platform for discovery and validation of potential cancer drug targets through oncogene synthetic lethal interactions which involve expression of recombinant activated oncogenes of interests and/or inhibition of tumor suppressors in human foreskin fibroblasts (HFF).
Learn more »
Highlight 5
Cord Blood Transplant
Breakthrough advances in cord blood stem cell expansion, banking and therapeutic application provide the foundation for an off-the-shelf product to significantly improve cord blood transplantation.
Learn more »
Highlight 6
Broad Spectrum Anti-Bacterial Drugs
Proprietary drug leads that are potential first-in-class, broad-spectrum antibiotics inhibiting both DNA gyrase and RecBCD/AddAB DNA repair enzymes. The lead compounds may have the potential to treat difficult infectious diseases such as tuberculosis and are less likely to become ineffective due to drug resistance.
Learn more »
1 of 1 | Next »

Your Bridge to Innovation

Fred Hutchinson Cancer Research Center works with industry and investment partners to commercialize its discoveries and maximize their impact on our mission of eliminating cancer and other diseases.

The Industry Relations and Technology Transfer Office serves as the bridge linking companies and investors to the Fred Hutch’s world-class discoveries and scientific faculty.

 

Fred Hutch's Value

  • Ranks in the top two in National Institutes of Health (NIH) funding among all U.S. independent research institutions
  • A leading recipient of National Cancer Institute (NCI) funding among academic and research institutions
  • Fiscal year 2012 budget of $419 million
  • More than 200 faculty and nearly 600 other scientists working across five scientific divisions
Business people talking

Our approach to these vital partnerships emphasizes relationship-building,
collaboration and shared success.

Contact us
so we can keep in touch about what's new at the Center and your business and research interests.

 

Available Technologies

Learn about our licensing opportunities on our Available Technologies page or by contacting us today.

Express Licensing

Learn about available research tools on our Express Licensing page.

Success Stories

Learn more about our portfolio companies and other partnerships on our Success Stories page.

Fred Hutchinson Cancer Research Center is a world leader in research to prevent, detect and treat cancer and other life-threatening diseases.